TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03633994
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
Study: NCT03633994
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline bladder instillation
Study: NCT02738580
Drug: COS with GnRH antagonists and HP-HMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
Study: NCT00247572
Drug: NRP104
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tab from 7th-11th day of the same cycle orally 3times/day
Study: NCT01062763
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 to 50 mg once daily
Study: NCT01062763
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: addition of placebo 1 to 2 tablets daily
Study: NCT03629769
Drug: Proxelan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one suppository of proxelan once a day for 30 days
Study: NCT00186901
Drug: Calcium carbonate (Tums), vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
Study: NCT02948959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT05258123
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with nine tables was administered
Study: NCT02372760
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy
Study: NCT00845507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Sterile solution in equivalent doses as Exenatide
Study: NCT01425853
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT02239081
Drug: Placebo for CTP-730
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01545440
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous dose every 4 weeks
Study: NCT02618720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02382653
Drug: oral perixicam
Normalized name: piroxicam Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral adminstration of buccal perixicam
Study: NCT01583738
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT02080195
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
Study: NCT01646853
Drug: cisplatin-fluorouracil chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
Study: NCT02632786
Drug: NEOD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Study: NCT02632786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Bag
Study: NCT01513863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied to affected area once a day for 70 days
Study: NCT01606397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (capsule)
Study: NCT00927355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician.
Study: NCT01069081
Drug: Arm C
Normalized name: Forearm Crutch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
Study: NCT01069081
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
Study: NCT01069081
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
Study: NCT04700475
Drug: citric acid solution
Normalized name: citric acid Topical Solution
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: citric acid solution applied as a mouth rinse
Study: NCT03072225
Drug: Herbal Medicine C-117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Medicine C-117 formula including 2 herbals and 2 insects
Study: NCT03072225
Drug: The Placebo of Herbal Medicine C-117
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo of Herbal Medicine C-117 formula including 4 herbals
Study: NCT02584478
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
Study: NCT00961896
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT00961896
Drug: LDE225 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00961896
Drug: LDE225 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03541044
Drug: Nicorette Mini Lozenge
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT02584478
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard
Study: NCT01872910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01872910
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03304873
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
Study: NCT00100932
Drug: E7389 21 Day Cycle
Normalized name: Ortho-Cyclen 21 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
Study: NCT01101334
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017, Two 0.25mg Tablets administered twice daily
Study: NCT03158935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
Study: NCT02584478
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken daily from Day 8 to Day 21 (14 days). Administered orally.
Study: NCT00538096
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Study: NCT00538096
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Study: NCT00538096
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
Study: NCT00988221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to tocilizumab was supplied as a sterile solution in vials.
Study: NCT02948881
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02006121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 9 mg/ml
Study: NCT00815035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat flour used as a placebo that is orally ingested a graded fashion
Study: NCT01904136
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02923999
Drug: P2G12 Dose Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
Study: NCT02923999
Drug: P2G12 Dose Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
Study: NCT02923999
Drug: P2G12 Dose Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
Study: NCT00001202
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04018885
Drug: ALA 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study: NCT04018885
Drug: ALA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study: NCT04018885
Drug: ALA 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study: NCT01367249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile ophthalmic solution
Study: NCT00154310
Drug: Enteric-coated mycophenolate sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
Study: NCT00310323
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as 4 ounces of Coca-Cola
Study: NCT00035802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
Study: NCT03625739
Drug: anti-tuberculosis drug
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention drugs are prescribed by treating caregiver
Study: NCT03866980
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01115985
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00790153
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral suspension given at one occasion.
Study: NCT00439829
Drug: Gonal F
Normalized name: Gonal F
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS.
Study: NCT01222468
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
Study: NCT00211978
Drug: calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
Study: NCT00211978
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
Study: NCT03101241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04203537
Drug: CA-008
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration during surgery
Study: NCT04203537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration during surgery
Study: NCT00562185
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01257412
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/10 mg Oral dose od
Study: NCT02306083
Drug: Placebo three times a day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02306083
Drug: glucosamine sulfate 1500 mg three times a day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01454453
Drug: Patients- dose titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose titration (patients) - 4-10 weeks
Study: NCT03395249
Drug: SPR994
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1.
Study: NCT03395249
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Study: NCT03395249
Drug: Orapenem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebipenem pivoxil granules
Study: NCT03604757
Drug: 68Ga-PSMA-617 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT Imaging with 68Ga-PSMA-617 injection
Study: NCT03604757
Drug: 68Ga-RM2 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT Imaging with 68Ga-RM2 injection
Study: NCT02906995
Drug: Sublingual tablet 4 mg versus Nicorette Lozenge 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge.
Study: NCT01336959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose matching placebo administered 2 prior to surgery
Study: NCT02330562
Drug: BEV
Normalized name: Bevespi
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
Study: NCT01849419
Drug: Within-subjects (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
Study: NCT01921777
Drug: Traumeel
Normalized name: Traumeel
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT03863899
Drug: Additional intraoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of any analgesics during the operation
Study: NCT03863899
Drug: Additional postoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of any analgesics within first 24 hours after the operation
Study: NCT05212493
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis oil 20:1 CBD:THC ratio
Study: NCT03326947
Drug: docetaxel, cisplatin and 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy
Study: NCT00003175
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01921777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT03779087
Drug: 10d TL quadruple therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
Study: NCT03779087
Drug: 10d AL quadruple therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
Study: NCT02171741
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous daily dosing for 20 or 13 days
Study: NCT02819687
Drug: RDX5791
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002757
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002757
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002757
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002757
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002757
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02501213
Drug: Spironolactone (+/- Furosemide)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
Study: NCT00702650
Drug: Testosterone MD-Lotion
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg to 120 mg administered topically once daily for 120 days
Study: NCT03017313
Drug: LHRH analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-or 6-month formulations
Study: NCT04097405
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Study: NCT00535743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
Study: NCT00688272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given QD x 6 days
Study: NCT00535743
Drug: Esmeron®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study: NCT00877903
Drug: Prochymal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells